paclitaxel has been researched along with Carcinoma, Intraepithelial in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Carlos, L; Colombo, P; De Cobelli, O; Duran-Merino, R; Guazzoni, G; Hurle, R; Lazzeri, M; Nohales, G; Santoro, A; Trapani, ED | 1 |
| Fan, H; Li, J; Lu, P; Qin, Y; Xu, L | 1 |
| Keegan, AD; Kingsley, C; Perry, A; Porter, HA; Tran, NL | 1 |
| Albarracin, C; Downs-Kelly, E; Gould, R; Hatzis, C; Morkowski, J; Peintinger, F; Sinn, B; Symmans, WF | 1 |
| Fernandez, RO; Iniesta, MD; Lu, KH; Malpica, A; Patrono, MG; Ramirez, PT; Salvo, G | 1 |
| Bassi, PF; D'Agostino, D; Franchini, S; Palermo, G; Racioppi, M; Renier, D; Rosato, A; Volpe, A | 1 |
| Bento, S; Dávila, C; Ferreira, A; Pereira, D; Rodrigues, A; Rodrigues, H; Vieira, C | 1 |
| Li, J; Lin, ZQ; Peng, YP; Wang, LJ; Zhang, BZ | 1 |
| Cao, D; Hruban, RH; Itami, A; Lee, KM; Maitra, A; Ouellette, MM; Pour, PM | 1 |
| Wang, HJ; Zheng, WX | 1 |
| Baile, WF; Beale, EA; Glober, GA; Kudelka, AP; Lenzi, R | 1 |
| Furukawa, T; Irie, K; Iwanaga, K; Katoh, O; Kuroki, S | 1 |
4 review(s) available for paclitaxel and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Incidence; Mutation; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Platinum Compounds; Salpingectomy | 2015 |
Neoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cesarean Section; Cisplatin; Female; Humans; Live Birth; Neoadjuvant Therapy; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Cervical Neoplasms | 2011 |
[Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma in Situ; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Paclitaxel; Precancerous Conditions; Radiotherapy, Adjuvant; Uterine Neoplasms | 2007 |
Discussing disease progression and end-of-life decisions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude to Death; Carcinoma in Situ; Cisplatin; Communication; Decision Making; Disease Progression; Euthanasia; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Physician-Patient Relations; Truth Disclosure | 1999 |
3 trial(s) available for paclitaxel and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Europe; Female; Humans; Hyaluronic Acid; Male; Middle Aged; Paclitaxel; Prospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm, Residual; Paclitaxel; Prognosis; Reproducibility of Results; Survival Rate; Tumor Burden | 2015 |
Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; BCG Vaccine; Biopsy, Needle; Carcinoma in Situ; Cystoscopy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyaluronic Acid; Italy; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2011 |
5 other study(ies) available for paclitaxel and Carcinoma, Intraepithelial
| Article | Year |
|---|---|
Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report.
Topics: Carcinoma in Situ; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gastrectomy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Lymph Node Excision; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Treatment Outcome | 2017 |
IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Female; Humans; Insulin Receptor Substrate Proteins; MCF-7 Cells; Neoplasm Grading; Neoplasm Invasiveness; Paclitaxel; Phosphorylation; Signal Transduction; STAT6 Transcription Factor; Transfection | 2013 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma in Situ; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma in Situ; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Tubulin | 2007 |
[A case of synchronous bilateral double primary lung cancer successfully treated by Nd-YAG laser therapy and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Laser Therapy; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Taxoids | 1999 |